Aims: With a prevalence of 16%, diabetes mellitus (DM) is one of the most frequent non-communicable comorbidities of tuberculosis (TB). DM is a major risk factor for adverse TB outcomes and may require personalized TB drug dosing regimens.
The dual burden of tuberculosis (TB) and diabetes mellitus (DM) is a major global public health problem. 1 In 2017, the World Health Organization reported 10 million cases of TB and 1.3 million TB-related deaths. 2 Approximately 415 million people worldwide live with DM and another 318 million people have impaired glucose tolerance-a marker for future diabetes. 3 By 2040, these numbers are likely to grow to 642 million and 481 million, respectively. 4 The global burden of TB-DM overlap is high, with a prevalence of 16% globally, 17% in Asia, 7% in Africa, 24% in North America, 23% in Oceania, 11% in South America, and 6% in Europe. 1 The International Diabetes Federation (IDF) estimates that 46% of diabetes cases worldwide (around 175 million) are not diagnosed, with the highest proportions concentrated in Africa (62%) and southeast Asia (54%), coinciding with the greatest TB burden. Globally, 84% of all people with undiagnosed diabetes live in low-income and middle-income countries where the management of these people is rarely optimal. 5 DM could severely threaten TB control and may become most profound in resource-poor areas where TB thrives. 6 A systematic review and meta-analysis of studies published between 1980-2010 reported that DM is associated with 69% higher risk of death and increased risk of TB relapse than TB patients without DM. 7 Since 2010, several large cohort studies reported unfavourable effects of DM on TB outcomes. DM was associated with more severe clinical manifestations of TB such as higher frequency of cavities on chest X-ray and higher hospitalization rates. [8] [9] [10] Patients with DM were more likely to have up to 2 times higher TB reactivation, recurrence, and relapse. [8] [9] [10] [11] TB-DM patients were more likely to have delayed sputum conversion and higher probability of treatment failure. 8, 9, 12 A recent systematic review showed that glycaemic control has a favourable effect on TB treatment outcomes and, conversely, uncontrolled DM or poor glycaemic control (i.e. HbA1c > 7%) was associated with delayed sputum conversion. 13, 14 Early screening for TB-DM comorbidity can help clinicians to act promptly, thereby resulting in improved TB treatment outcomes. 15 Notably, given the profound impact of DM comorbidity on TB treatment outcomes and the call for intensified precision drug therapy, this comorbidity should receive higher priority in prospective randomized clinical TB drug efficacy trials. However, an overview of current data on TB-DM comorbidity in recent TB drugs trials is lacking. This overview may help to raise awareness on the inclusion of DM comorbidity and could benefit the design of future TB drug trials. We therefore aimed to systematically review the inclusion of DM comorbidity in recent TB drug efficacy trials, with specific emphasis on differential outcomes of TB-DM overlap patients. 
| Information sources and search strategy
In this review, the PubMed, Science Direct and ClinicalTrials.gov databases were systematically searched (in September 2017) for TB drug trials published between 1 January 2012 and 12 September 2017 using combinations of the keywords "tuberculosis", AND "drug" AND "trial". Full search criteria can be found in Supporting information Appendix S2.
| Inclusion criteria
The following eligibility criteria were applied for studies to be considered for inclusion: (i) published in peer-reviewed journals; (ii) clinical trials or interventional studies of TB drug efficacy in TB confirmed (i.e. sputum smear or culture positive) patients that have been completed and published; and (iii) in English 16 and reflecting an original study. All criteria were required to be met for inclusion.
What is already known about this subject 
| Study measures and outcomes
The primary outcome of interest was the percentage of TB drug trials performed around the world that included DM patients. Additionally, results were assessed per continent. Exploratory, more descriptive outcomes included differential outcomes of TB-DM patients (if reported). Chi-square tests were performed to assess potential statistical differences in inclusion (yes/no) of DM comorbidity across subgroups (e.g. type of TB and continent were trials were performed). A P-value <.05 was considered statistically significant.
| Assessment of reporting bias
To assess potential reporting bias, we searched for study protocols of each study to check recruitment criteria of DM patients in the eligible trials against reported population characteristics. If unclear, we contacted the study authors to get more information about the DM criteria and reported outcomes.
3 | RESULTS
| Study selection
After duplicates were removed, a total of 1177 records were screened based on abstract and title. We identified 54 potentially eligible fulltext papers of which 13 studies were excluded after detailed review (10 studies were noninterventional, and 3 assessed a diagnostic tool or the pharmacokinetics of TB drugs and not the efficacy of the TB drug itself). A flow diagram is presented in Figure 1 and study characteristics of the final selection of 41 trials are presented in Table 1 .
Eligibility decisions for in-and excluded studies have been provided in Supporting information Appendix S3. Of note, compared to our initial study protocol we did not apply the full-text being available as an inclusion criterion, given that we did not restrict ourselves to online available full-texts only but also contacted study authors to retrieve full-texts.
| Study characteristics
The vast majority of TB drug trials was exclusively performed in Asia (n = 15; 37%) and Africa (n = 13; 32%). North America (USA) and South America (Brazil) contributed only one trial each, while others were performed in Europe (n = 2, both in Georgia) or in multiple sites around the world (n = 9). Study size varied between 31 patients for a TB trial performed in Georgia 25 and 1931 for a multicentre trial with moxifloxacin. 47 Drugs mostly studied were isoniazid, rifampicin, pyrazinamide and ethambutol. 19 with overall median DM prevalence of 12.3%. Naturally, in the study that specifically focused on TB-DM overlap, this was 100%. 23 Three out of 12 trials reporting DM comorbidity showed that DM was the most common comorbidity. [37] [38] [39] Of the 12 trials reporting DM comorbidity, none of the studies assessed any potential effects of DM on anti-TB drugs outcomes. Of note, 6 out of 9 (67%) drug trials for drug-resistant TB included DM comorbidity in their baseline characteristics, while only 4 out of the 32 (12.5%) drugsusceptible TB trials included DM comorbidity in their baseline characteristics, and this differed significantly (P = .003).
| Overview of DM comorbidity in TB drug trials

| DISCUSSION
Data from this systematic review indicate that <1/3 recent TB drug efficacy trials reported the inclusion of patients with DM comorbidity regardless of DM severity. If included, diagnostic criteria for DM were often unclear. Notably, inclusion of DM was relatively higher in MDR-TB drug trials and trials performed in Asia. Although DM patients were included in some studies, no differential outcomes for DM-TB overlap patients were reported.
Asia has high DM prevalence among TB patients; therefore, it is not surprising that most trials that included DM comorbidity were conducted in Asia, mainly China. China and India are 2 leading countries that have piloted theTB-DM collaborative framework and have demonstrated bidirectional screening for both diseases. [57] [58] [59] Although India is one of the pilot countries, most drug trials conducted in India had unclear criteria for DM comorbidity, and one Indian trial even excluded DM patients. Most trials that excluded DM comorbidity were conducted in Africa. Notably, South Africa has high prevalence of TB, and TB ranks third in diseases that causes life-years lost, 60 but none of the TB drug trials conducted in South Africa screened for DM comorbidity.
For South Africa, this omission may be related to the relatively low comorbid DM rates compared with, for example, comorbid human immunodeficiency virus/acquired immune deficiency syndrome. However, the few TB drug trials conducted in America also did not assess DM comorbidity, while DM rates in these continents are relatively high. 1 In particular, multidrug-resistant TB (MDR-TB) continues to be a public health crisis and in MDR-TB the importance of DM comorbidity seems more widely acknowledged. Indeed, in a meta-analysis it was
shown that DM was an independent risk factor for MDR-TB and, in most drug-resistant TB trials, DM comorbidity was more often included. 61 Regarding the effect of DM comorbidity to unfavourable treatment of TB, none of the TB trials that included DM comorbidity reported specific outcomes related to theTB-DM subpopulation. A systematic review suggested a phase III clinical trial to ensure the safe use of new TB drugs in diabetes patients. 62 Indeed, there is still a lack of sufficient data regarding pharmacokinetic and clinical data of TB drugs in DM patients, despite the continuous growth of DM patients in the future that will cause a further threat to TB control.
Some TB drug trials excluded insulin-dependent DM patients.
Insulin-dependent diabetes will usually reflect uncontrolled DM. 63 As TB patients with uncontrolled DM are more likely to fail on treatment, trials that are specifically designed to show efficacy of a new TB drug usually exclude those patients as they could compromise trial results. 64 Several underlying mechanisms to understand adverse treatment outcomes of TB due to hyperglycaemia have been suggested. 65, 66 One mechanism is related to an altered immunological response [67] [68] [69] which is important, but difficult to account for in TB treatment decisions. Another factor that explains unfavourable treatment outcomes are the drug-drug and drug-disease interactions. A systematic Including DM comorbidity in TB drug trials will allow for the study of possible DM-TB drug-drug and drug-disease interactions that can alter the pharmacokinetics, safety and clinical effects of the TB drugs.
Eventually, these findings will enable us to assess TB-DM patients'
individual need for personalize treatment options and lead to better real-world TB-DM outcomes and possibly lower resistance rates.
| CONCLUSION
To conclude, current inclusion of DM comorbidity in recent TB drug efficacy trials is suboptimal compared with its increasing prevalence and significance. Considering the considerable prevalence and impact of DM comorbidity, the inclusion of patients with DM in future TB efficacy drug trials warrants increased attention and requires a joint effort of trialists, clinicians and policy makers alike.
| Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY. 73 
